Sanofi and Teva Report Positive Long-Term Data for Duvakitug in Inflammatory Bowel Disease
Teva and Sanofi reported positive 44-week data from the RELIEVE UCCD long-term extension study of duvakitug, showing durable efficacy in ulcerative colitis and Crohn's disease patients.
Teva Pharmaceutical Industries and Sanofi announced positive results from the RELIEVE UCCD long-term extension (LTE) study of duvakitug, an investigational human monoclonal antibody targeting TL1A. The trial showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis (UC) and Crohn's disease (CD) that initially responded to the induction phase.
RELIEVE UCCD LTE is a double-blind randomized study evaluating the long-term efficacy, safety, and tolerability of duvakitug in UC and CD, the two most common forms of inflammatory bowel disease (IBD).
These longer duration data reinforce the efficacy from the RELIEVE UCCD Phase IIb induction study, which demonstrated that patients achieved clinically meaningful response with duvakitug compared to placebo at week 14.
Four Phase III studies of duvakitug are already underway.